Artwork

Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Gliobastoma + New View on Clinical Trials... Dr. Fahar Merchant, President & CEO Medicenna Therapeutics

22:38
 
Share
 

Manage episode 374421519 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics.

  continue reading

90 episodes

Artwork
iconShare
 
Manage episode 374421519 series 3360496
Content provided by BioTech Nation Team and Moira Gunn. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by BioTech Nation Team and Moira Gunn or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Glioblastoma is the most aggressive form of brain cancer, and progress in treating Glioblastoma has been elusive. Now, Toronto-based Medicenna has completed a successful Phase 2 with its innovative drug, and is now deep into planning the Phase 3 Trial. Also of interest, the FDA agreed to an unprecedented approach in Phase 2, which not only yields better science, but reduces the cost of the clinical trials themselves. To be sure, this approach will be carried forward into Phase 3. Dr. Fahar Merchant is the President & CEO of Medicenna Therapeutics.

  continue reading

90 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide